Another study that provides insights into the potential impact of MITF mutations on treatment response in the context of BRAF and NRAS mutations found that melanomas with concurrent NRAS and MITF mutations had distinct gene expression patterns and exhibited resistance to MAPK pathway inhibition. The gene discussed is MITF; the disease is melanoma.